Daniele Oliveira^1,2,3, Adriana Ribeiro³*, Helena Cabral-Marques³ and Diogo Sousa-Martins³

¹Department of Ophthalmology, Centro Hospitalar de Setúbal, Portugal
²Department of Ophthalmology, Hospital da Luz Setúbal, Portugal
³Department of Pharmacy, Pharmacology and Health Technologies, Research Institute for Medicine, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal

*Corresponding Author:Adriana Ribeiro, Research Institute for Medicine, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.

Received: June 07, 2024; Published: July 05, 2024

Abstract

Background: This proof of concept (PoC) study employs a multifaceted approach and focuses on collaboration's impact in preventing basal cell carcinoma (BCC), a predominant form of skin tumors occurring in the eyelid. Methods: The first phase includes a literature review spanning 2010-2023, where relevant data from PubMed and Web of Science are collected and analyzed. Specific criteria are applied to filter articles, aiming to identify trends, and gaps in existing research. The second phase focuses on clinical data analysis at Centro Hospitalar de Setúbal, Portugal (CHSP), involving the retrieval and analysis of diagnostic records of suspicious eyelid malignant lesions. The third phase entails a community perception survey on self-care and prevention, employing anonymous surveys distributed via Quick Response codes (QR codes) and Google Forms to hospital visitors and patients. Targeted interventions and educational programs, including ABCDE rule criteria for distinguishing malignant lesions, guide physicians and pharmacists in the early detection of eyelid BCC.

Results: Among the 350 initially screened articles, a total of 55 articles were selected, aligning with our objectives. Within this subset, a correlation was found between eyelid BCCs and Portugal (n = 1) and Ophthalmology (n = 10). Regarding self-care and prevention strategies by analyzing responses from 201 patients. Lastly, results showed that the implemented the Clinical “ABCDE” Rule for Pharmacist-Physician Collaboration, aiming to guide patients towards early detection and treatment is a valuable assessment technique for identifying suggestive tumor lesions and optimizing patient care.

Conclusion: Overall, the coordinated efforts of the three study phases provide promising insights into collaborative strategies and actively facilitate pharmacist-physician collaboration in promptly identifying malignant indicators for effective eyelid BCC prevention.

Keywords: Non - Strabismic Binocular Dysfunction; Convergence Insufficiency; Convergence Excess; Accommodative Disorders

References

1. Abbasi Naheed R., et al. “Early Diagnosis of Cutaneous Melanoma”. JAMA 22 (2004): 2771.
2. Allemani Claudia., et al. “Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries”. The Lancet10125 (2018): 1023-1075.
3. Baek Se Hyun and Mi Jung Chi. “Clinical Analysis of Benign Eyelid and Conjunctival Tumors”. Ophthalmologica 1 (2006): 43-51.
4. Basset-Seguin N and F Herms. “Update in the Management of Basal Cell Carcinoma”. Acta Dermato Venereologica11 (2020): adv00140.
5. Biazim Débora F., et al. “Eyelid malignancies in young individuals: clinical peculiarities”. International Ophthalmology6 (2022): 1867-1874.
6. Binns Colin W., et al. “Problems and Prospects: Public Health Regulation of Dietary Supplements”. Annual Review of Public Health 1 (2018): 403-420.
7. Burgic Mufid., et al. “Clinical Characteristics and Outcome of Malignant Eyelid Tumors: A Five-Year Retrospective Study”. Medical Archives 3 (2019): 209-212.
8. Chmiel Paulina., et al. “Novel Approaches in Non-Melanoma Skin Cancers—A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC)”. Cells20 (2022): 3210.
9. Cisek Paweł., et al. “Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye”. Cancers 6 (2021): 1425.
10. Daniele Oliveira., et al. “The Importance of Social pharmacy in the Prevention of Ophthalmology Eyelid Tumors”. In 13 th iMed.ULisboa Postgraduate Students Meeting. Ed. Faculty of Pharmacy, Universidade de Lisboa Research Institute for Medicines, 1-56. Lisbon: 13th, 5AD.
11. Downes Jessica M., et al. “Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center”. Journal of the American Pharmacists Association5 (2022): 1596-1605.
12. Félix Jorge., et al. “Social and economic value of Portuguese community pharmacies in health care”. BMC Health Services Research1 (2017): 606.
13. Fernando Fernandez-Llimos., et al. “Improving the quality of publications in and advancing the paradigms of clinical and social pharmacy practice research: the Granada statements”. International Journal of Pharmacy Practice xx (2023): 1-7.
14. Fowler Terri., et al. “Enhancing primary care and preventive services through Interprofessional practice and education”. Israel Journal of Health Policy Research1 (2020): 12.
15. Galindo-Ferreiro Alicia., et al. “Characteristics and recurrence of primary eyelid basal cell carcinoma in central Spain”. Journal of Current Ophthalmology2 (2020): 183.
16. Harvie Michelle. “Nutritional Supplements and Cancer: Potential Benefits and Proven Harms”. American Society of Clinical Oncology Educational Book 34 (2014): e478-e486.
17. Hidalgo Leonel., et al. “Dermoscopy as an aid in the differentiation of recurrent eyelid basal cell carcinoma versus apocrine hidrocystoma”. Dermatology Practical and Conceptual 2 (2022): e2022090.
18. Huang Jiancheng., et al. “Metabolic signature of eyelid basal cell carcinoma”. Experimental Eye Research 198 (2020): 108140.
19. Khaira Manmeet., et al. “The Evolving Role and Impact of Integrating Pharmacists into Primary Care Teams: Experience from Ontario, Canada”. Pharmacy4 (2020): 234.
20. Kim John YS., et al. “Guidelines of care for the management of basal cell carcinoma”. Journal of the American Academy of Dermatology3 (2018): 540-559.
21. Liu Jiaxi and Baoqiang Song. “Review of complications in double eyelid surgery”. Indian Journal of Ophthalmology5 (2022): 1460.
22. Marzuka AG and Book SE. “Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management”. Yale Journal of Biology and Medicine 2 (2015): 167-179.
23. McAlinden Colm., et al. “Hordeolum: Acute abscess within an eyelid sebaceous gland”. Cleveland Clinic Journal of Medicine 5 (2016): 332-334.
24. Nour Nofal., et al. “Basal cell carcinoma (BCC) of the lower eyelid is an actinic induced cancer: The ABCDE concept to explain the relationship between the invasiveness of BCC and actinic damage”. ARVO Annual Meeting 7 (2020): 4677.
25. Oliveira D., et al. “Eyelid and Conjunctiva Epithelial Tumours: A Review of Risk Factors and Primary Prevention Options”. ARC Journal of Ophthalmology1 (2021): 21-29.
26. Oliveira D. Almada S. Lesões palpebrais “não parece mas é, É mas não parece…”. Lisbon, (2022).
27. Oliveira D and Bacalhau C. “Ocular Tumors and Prevention Against Ultraviolet”. In Casa da Baía Auditorium, Sponsor Brill Pharma S. L. Lisbon, (2020).
28. Oliveira Daniele., et al. “Incidence of malignant eyelid tumors: A 6-year period review (2015-2021)”. The Pan-American Journal of Ophthalmology1 (2024).
29. Pe’er Jacob. “Pathology of eyelid tumors”. Indian Journal of Ophthalmology3 (2016): 177.
30. Prídavková Zuzana., et al. “Recurrent Periocular Basal Cell Carcinoma. Case Report”. Czech and Slovak Ophthalmology4 (2021): 208-213.
31. Ramgopal Archana., et al. “A chronic eyelid lesion in a child: multi-disciplinary approach to diagnosis, treatment and management of a highly atypical histiocytic lesion”. Pediatric Hematology and Oncology2 (2022): 180-186.
32. Rene C. “Oculoplastic aspects of ocular oncology”. Eye 2 (2013): 199-207.
33. Ribeiro Nadine., et al. “Primary health care policy and vision for community pharmacy and pharmacists in Portugal”. Pharmacy Practice3 (2020): 2043.
34. Sato Yasuyoshi., et al. “Squamous cell carcinoma of the eyelid”. Japanese Journal of Clinical Oncology (2023).
35. Seidl‐Philipp Magdalena., et al. “Known and new facts on basal cell carcinoma”. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 7 (2021): 1021-1041.
36. Shi Yingyun., et al. “Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment”. OncoTargets and Therapy 10 (2017): 2483-2489.
37. Stokkermans Thomas J and Mark Prendes. “Benign Eyelid Lesions”. StatPearls. Ilha do Tesouro (FL): StatPearls, (2023).
38. Teng Yan., et al. “Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective”. Frontiers in Public Health 9 (2021).
39. Ul Kadir Syeed Mehbub., et al. “Clinicopathological Analysis and Surgical Outcome of Eyelid Malignancies: A Study of 332 Cases”. Journal of Skin Cancer 2022 (2022): 1-9.
40. Vaccari Sabina., et al. “Basal cell carcinoma of the eyelid margin: Dermoscopic clues in a case series”. Dermatologic Therapy4 (2021).
41. Valliant Samantha N., et al. “Pharmacists as accessible health care providers: quantifying the opportunity”. Journal of Managed Care and Specialty Pharmacy1 (2022): 85-90.
42. Weinstock Martin A., et al. “Tretinoin and the Prevention of Keratinocyte Carcinoma (Basal and Squamous Cell Carcinoma of the Skin): A Veterans Affairs Randomized Chemoprevention Trial”. Journal of Investigative Dermatology6 (2012): 1583-1590.
43. Al Wohaib Manar., et al. “Characteristics and factors related to eyelid basal cell carcinoma in Saudi Arabia”. Middle East African Journal of Ophthalmology2 (2018): 96.
44. Wójcicki Piotr and Mateusz Zachara. “Surgical Treatment of Eyelid Tumors”. Journal of Craniofacial Surgery2 (2010): 520-525.
45. Yacob Filmon., et al. “Weakly supervised detection and classification of basal cell carcinoma using graph-transformer on whole slide images”. Scientific Reports1 (2023): 1-10.
46. “Código Deontológico da Ordem dos Farmacêuticos”. Diário da República n.o 244/2021, Série II de 2021-12-20, (2021).

Citation

Citation: Adriana Ribeiro., et al. “Pharmacist-Physician Collaboration for the Prevention and Treatment of Eyelid Basal Cell Carcinoma". Acta Scientific Ophthalmology 7.8 (2024): 16-26.

Copyright

Copyright: © 2024 Daniele Oliveira., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.